Pharmaceuticals in Brazil Potential Addressable Market

Addressable Market Calculation

1. Green-chemistry, large-scale API campuses for cardiovascular & anti-infective drugs

• Key Assumptions and Detailed Rationale:

  • Estimated Annual Value of Imported APIs in Brazil: The whitespace directly addresses the heavy reliance on imported Active Pharmaceutical Ingredients (APIs), which constitute approximately 90% of the APIs used in Brazil. The potential market is the value of these imports that can be substituted by domestic production. Without a direct figure for total API import value in the provided text or readily available recent search results, this must be estimated. Brazil's total pharmaceutical market moved approximately R$ 220.9 billion in 2024. API costs are a significant component of drug production, varying by drug complexity. Assuming API costs represent, on average, 15% to 40% of the final pharmacy purchase price (a broad industry estimate), and acknowledging this is a simplification, the total value of APIs consumed annually could be estimated. Since 90% are imported, the value of imported APIs is a portion of this total API consumption. A reasonable estimate for the annual value of imported APIs, considering the total market size and typical API cost ranges, is between R$ 40 billion and R$ 60 billion.
  • Estimated Percentage of Imported API Market for Target Classes (Cardiovascular & Anti-infective): The whitespace specifically targets cardiovascular and anti-infective drugs. The provided text mentions anti-infectives are among the top purchases by the SUS, implying a significant market volume for these classes. Cardiovascular diseases are also highly prevalent. Estimating the portion of the total imported API market specifically for these two broad therapeutic categories is necessary. Based on their prevalence and typical treatment costs, assuming they represent between 20% and 40% of the total imported API value is a reasonable range.
  • Potential Percentage of Imported API Market Captured: The whitespace proposes "large-scale API campuses" and is supported by government initiatives aimed at increasing domestic production ("Nova Indústria Brasil"). This indicates a potential to capture a meaningful share of the currently imported volume. While substituting 90% quickly is unrealistic, achieving 10% to 20% capture of the relevant imported market segment over the 2024-2028 timeframe, supported by significant investment and policy, is an ambitious but plausible target for a large-scale initiative.

• Researched Numbers with Rationale and Sources:

  • Total Pharmaceutical Market Movement (2024): R$ 220.9 billion. Used as a basis for estimating total API consumption value.
  • API Import Reliance: Approximately 90% of APIs are imported. Used to define the market opportunity (substituting imports).
  • Domestic Input Production: Only about 5% of inputs are produced domestically. Reinforces the scale of the import substitution opportunity.
  • Public Preference for Local Production: 90% of Brazilians favour local production. Indicates demand-side support for domestic API initiatives.
  • Government Support: "Nova Indústria Brasil" program aims to strengthen domestic production of medicines and inputs. Supports the feasibility of capturing a significant market share.
  • Therapeutic Class Relevance: Anti-infectives are top SUS purchases. Supports the selection of this class as a relevant target.
  • Rationale for Estimated Numbers: The estimated R$ 40-60 billion annual value of imported APIs, 20-40% share for target classes, and 10-20% capture rate are based on the overall market size, the high import dependency stated in the sources, the noted importance of the therapeutic classes, and a realistic assessment of market penetration potential over the timeframe for a large-scale, supported initiative, in the absence of specific, granular data in the provided text or available searches.

• Calculated Potential Addressable Market:

  • Formula: (Estimated Annual Value of Imported APIs in Brazil) * (Estimated % of Imported API Market for Target Classes) * (Potential % of Imported API Market Captured)
  • Lower Bound Calculation: R$ 40 billion * 20% * 10% = R$ 0.8 billion per year
  • Upper Bound Calculation: R$ 60 billion * 40% * 20% = R$ 4.8 billion per year
  • Potential Addressable Market Range (Annual): R$ 0.8 billion to R$ 4.8 billion

2. Domestic CDMO hub for monoclonal antibodies & cell/gene-therapy starting materials

• Key Assumptions and Detailed Rationale:

  • Estimated Annual Value of the Biologics Market in Brazil: The whitespace focuses on high-value, complex medicines. The text highlights the growing market for biologics and biosimilars and notes that oncology biologics spend grows significantly (>18% YoY). While a total market size for biologics isn't explicitly given, they represent a substantial and growing segment of the pharmaceutical market. Estimating this value is crucial. Assuming biologics account for a significant portion of the total market value (R$ 220.9 billion), due to their high cost, a range of 10% to 20% of the total market seems plausible. This results in an estimated annual biologics market value between R$ 22 billion and R$ 44 billion.
  • Potential Percentage of This Market Captured by a Domestic CDMO: A Contract Development and Manufacturing Organization (CDMO) provides manufacturing services to other pharma companies. The opportunity is to capture manufacturing contracts for biologics that are currently imported, produced internally by MNCs, or represent new biosimilar/biologic pipelines from national players. The whitespace mentions capturing production for monoclonal antibodies and cell/gene therapy materials, complex areas with high value. With investments noted in biotechnology and PPPs, capturing 5% to 15% of the value of the estimated total biologics market through contract manufacturing services over the 2024-2028 period represents the potential business for the CDMO. This percentage reflects securing manufacturing deals for a portion of the products within this market size.

• Researched Numbers with Rationale and Sources:

  • Total Pharmaceutical Market Movement (2024): R$ 220.9 billion. Used as a basis for estimating biologics market size.
  • Biologics Market Growth: Oncology biologics spend grows >18% YoY. Indicates significant growth and market size within the biologics segment.
  • Investment in Biotechnology: Eurofarma Ventures US$100M fund, BNDES/Finep/Butantan fund. Signals offer-side investment and potential for domestic capability.
  • Public Labs Focus: Butantan/Bionovis cover insulin & EPO, implying other biologics manufacturing capacity is limited or held by MNCs. Supports the premise of a whitespace for complex biologics manufacturing.
  • Rationale for Estimated Numbers: The estimated R$ 22-44 billion annual biologics market value and the 5-15% capture rate are based on the overall market size, the noted high growth and cost of biologics, and an assessment of the potential for a new CDMO to secure contracts for a portion of this market's manufacturing needs, supported by observed investment trends.

• Calculated Potential Addressable Market:

  • Formula: (Estimated Annual Value of the Biologics Market in Brazil) * (Potential Percentage of This Market Captured by a Domestic CDMO)
  • Lower Bound Calculation: R$ 22 billion * 5% = R$ 1.1 billion per year
  • Upper Bound Calculation: R$ 44 billion * 15% = R$ 6.6 billion per year
  • Potential Addressable Market Range (Annual): R$ 1.1 billion to R$ 6.6 billion

3. White-label “tele-pharmacy + nurse” platform for chronic-disease adherence

• Key Assumptions and Detailed Rationale:

  • Number of Target Pharmacies (Independent & Associative): The whitespace targets independent pharmacies, which currently lack the digital capabilities of larger chains but represent a large number of establishments. There were approximately 93,700 pharmacies/drugstores in Brazil in 2024. Large chains (RD Saúde, DPSP, Pague Menos) dominate in revenue and consumer share but represent a smaller portion of the total number of stores. Estimating the number of independent and associative pharmacies is necessary. Based on the total number of establishments and the approximate number of stores operated by large chains (estimated 7,000-12,000), the number of independent and associative pharmacies is estimated to be between 80,000 and 85,000. These are the primary potential customers for a white-label platform.
  • Potential Adoption Rate: Adoption of new technology, especially by smaller businesses, takes time. A realistic adoption rate among the target pharmacies over the 2024-2028 period, driven by the need to compete and offer digital services (e-prescriptions, telemedicine integration), is estimated to be between 5% and 15%.
  • Average Annual SaaS Revenue per Pharmacy: The platform offers valuable services like e-Rx integration, nurse chat, and delivery scheduling, which can improve patient adherence and generate new service revenue for pharmacies. The price of a B2B SaaS platform varies. Assuming a monthly fee that provides clear ROI to the pharmacy, a range of R$ 300 to R$ 800 per month seems plausible, translating to R$ 3,600 to R$ 9,600 per year per subscribing pharmacy.

• Researched Numbers with Rationale and Sources:

  • Total Number of Pharmacies/Drugstores (2024): ~93,700 establishments. Used as the base for estimating the number of independent pharmacies.
  • Large Chain Market Presence: Top 3 chains concentrate ~40% of main consumers; Abrafarma networks (large chains) represent >47% of retail revenue with ~12% of establishments. Indicates high productivity and market share of chains, reinforcing that independents are the primary target for a white-label solution.
  • E-prescription Law Active: The legal framework supports digital prescription services. Indicates regulatory readiness for this type of platform.
  • Consumer Embrace of Omni-channel: Consumers use chain apps. Shows consumer readiness for digital pharmacy interactions.
  • Rationale for Estimated Numbers: The estimated 80,000-85,000 target pharmacies are derived from the total number of establishments minus an estimate for large chain stores based on market share data. The 5-15% adoption rate and R$ 3,600-9,600 annual revenue per pharmacy are assumptions based on typical SaaS adoption curves and plausible pricing for value-adding services in the SMB segment, in the absence of specific data on digital platform pricing for Brazilian pharmacies.

• Calculated Potential Addressable Market:

  • Formula: (Number of Target Pharmacies) * (Potential Adoption Rate) * (Average Annual SaaS Revenue per Pharmacy)
  • Lower Bound Calculation: 80,000 * 5% * R$ 3,600 = R$ 14.4 million per year
  • Upper Bound Calculation: 85,000 * 15% * R$ 9,600 = R$ 122.4 million per year
  • Potential Addressable Market Range (Annual): R$ 14.4 million to R$ 122.4 million

4. Rural/interior cold-chain logistics network (drones, river barges, solar hubs)

• Key Assumptions and Detailed Rationale:

  • Estimated Annual Value of Cold-Chain Pharmaceutical Logistics Spend in Rural/Interior Brazil: The whitespace addresses the significant challenge of distributing temperature-sensitive pharmaceuticals to remote areas, citing recurrent spoilage and stock-outs. The market opportunity is providing the logistics service itself. Distributors handled 57% of the volume and 55.7% of the value (R$ 88.3 billion) of retail sales in 2024. A portion of this requires cold chain. Estimating this portion and the cost of distributing it to challenging rural/interior areas is key. Assuming 15% to 30% of retail value distributed requires cold chain (R$ 13.2-26.5 billion total cold chain value distributed), and 10% to 25% of this cold-chain value goes to rural/interior areas (R$ 1.32-6.63 billion cold chain value in target areas). The logistics cost for complex cold chain to remote areas is higher than standard. Assuming logistics costs are 20% to 35% of the product value in these areas gives an estimated annual logistics spend range.
  • Potential Percentage of This Logistics Spend Captured by a Specialized Network: A specialized network using innovative methods (drones, barges, solar hubs) aims to provide a more reliable and potentially cost-effective solution in these difficult regions. Capturing 10% to 25% of the estimated annual logistics spend in this specific, challenging segment over the 2024-2028 timeframe represents a plausible market share for such a dedicated network.

• Researched Numbers with Rationale and Sources:

  • Distribution Volume/Value (2024): Distributors handled 57% volume (4.6 billion units) and 55.7% value (R$ 88.3 billion PPP) of retail sales. Used to estimate the total scale of distribution.
  • Logistical Challenges: Text highlights logistical hurdles in Brazil's vast territory for temperature-sensitive products (RDC 430/2020). Defines the problem the whitespace addresses.
  • Rural Pain Points: Recurrent vaccine spoilage and stock-outs in Amazon/Northeast. Provides specific evidence of the problem in target areas.
  • Rationale for Estimated Numbers: The estimated annual cold-chain logistics spend in rural/interior areas (R$ 0.26-2.32 billion) is a multi-step estimation based on total distributed value, assumed cold-chain portion, assumed rural/interior portion, and assumed logistics cost percentage for challenging routes, due to lack of direct data. The 10-25% capture rate is an assumption of market penetration for a specialized service.

• Calculated Potential Addressable Market:

  • Formula: (Estimated Annual Value of Cold-Chain Pharmaceutical Logistics Spend in Rural/Interior Brazil) * (Potential Percentage of This Logistics Spend Captured by a Specialized Network)
  • Estimated Annual Logistics Spend Range: R$ 0.26 billion - R$ 2.32 billion
  • Potential Percentage Captured: 10% - 25%
  • Lower Bound Calculation: R$ 0.26 billion * 10% = R$ 0.026 billion = R$ 26 million per year
  • Upper Bound Calculation: R$ 2.32 billion * 25% = R$ 0.58 billion = R$ 580 million per year
  • Potential Addressable Market Range (Annual): R$ 26 million to R$ 580 million

5. AI-assisted regulatory-affairs SaaS (Portuguese) that drafts ANVISA dossiers

• Key Assumptions and Detailed Rationale:

  • Number of Target Pharmaceutical Companies in Brazil: The market for this SaaS is pharmaceutical companies operating in Brazil that need to submit dossiers to ANVISA for drug registration and variations. This includes manufacturers and importers. While an exact number isn't provided, hundreds of companies are authorized by ANVISA. Estimating the number of companies actively engaged in dossier submissions to be between 500 and 700 is a reasonable range.
  • Potential Penetration Rate: Adoption of AI tools in regulatory affairs is a growing trend. A realistic penetration rate among the target companies over the 2024-2028 period, driven by the need for efficiency and faster time-to-market, is estimated to be between 10% and 25%.
  • Average Annual SaaS Fee per Company: The value proposition is significant: reducing time, effort, and potentially cost associated with complex dossier preparation, which currently causes delays costing the industry significantly in lost sales. A B2B SaaS fee would depend on the level of AI assistance and company size. Assuming an average annual fee range of R$ 50,000 to R$ 200,000 per company, based on the value delivered in a high-cost, high-impact function like regulatory affairs, is plausible.

• Researched Numbers with Rationale and Sources:

  • Regulatory Burden/Delays: Industry cites regulatory burden as a top non-cost barrier; product launch delay averages 12–18 months vs. US/EU. These pain points highlight the need for efficiency solutions.
  • Cost of Delays: Launch delays cost >R$ 1 Bn/yr in lost sales (FarmaBrasil). This quantifies the potential value of speeding up the process.
  • Rationale for Estimated Numbers: The estimated 500-700 target companies are based on general knowledge of the number of pharma entities authorized by ANVISA. The 10-25% penetration rate and R$ 50,000-200,000 annual SaaS fee per company are assumptions reflecting typical early technology adoption in a specialized B2B market and plausible pricing based on the perceived high value of streamlining regulatory processes.

• Calculated Potential Addressable Market:

  • Formula: (Number of Target Pharmaceutical Companies) * (Potential Penetration Rate) * (Average Annual SaaS Fee per Company)
  • Lower Bound Calculation: 500 * 10% * R$ 50,000 = R$ 2.5 million per year
  • Upper Bound Calculation: 700 * 25% * R$ 200,000 = R$ 35 million per year
  • Potential Addressable Market Range (Annual): R$ 2.5 million to R$ 35 million

6. Outcome-based contracting toolkit for SUS (software + actuarial support)

• Key Assumptions and Detailed Rationale:

  • Estimated Annual SUS High-Cost Drug Spend: The whitespace targets public procurement, specifically for high-cost drugs (biologics, rare diseases) where outcome-based contracts (OBCs) are most applicable to manage expenditure and ensure value. The SUS is a major purchaser. While a precise total SUS pharma spend for 2024 is not given, the overall market is R$ 220.9 billion. Estimating SUS spend as a significant portion of this (e.g., 20-35% of market value) and the portion of SUS spend on high-cost drugs (e.g., 30-50%) provides a range for the value of drugs potentially managed by OBCs. This results in an estimated annual SUS high-cost drug spend between R$ 13.2 billion and R$ 38.5 billion.
  • Potential Percentage of This Spend Managed via OBCs Using the Toolkit: OBCs are currently used in limited pilots. The toolkit enables broader adoption. Over 2024-2028, assuming 1% to 5% of this high-cost drug spend could be managed through OBCs facilitated by the toolkit is a plausible range for initial market penetration.
  • Potential Value Capture by the Toolkit Provider (% of Managed Spend): The value of the toolkit lies in enabling the complex process of OBCs, potentially leading to cost savings or improved patient outcomes for the SUS. The provider could capture value as a percentage of the drug value managed under these contracts. A capture rate of 0.05% to 0.15% of the value of drugs managed via OBCs using the platform represents a small percentage of the overall drug cost but significant value for the toolkit provider, reflecting the service's contribution to managing high expenditures. (Note: This was adjusted from the thought process's higher range after recalculating, to better align with a percentage of managed spend rather than potential savings, which are harder to estimate).

• Researched Numbers with Rationale and Sources:

  • SUS as Major Purchaser: SUS is a significant player in the value chain.
  • Biologics Budget Growth: State secretariats face 15% YoY biologics budget growth. Highlights the cost pressure driving interest in OBCs.
  • OBC Examples Abroad: Mention of international examples (hep-C cure pay-per-SVR). Shows the model exists and could be adapted.
  • Fragmented SUS Data: Challenge noted for RWD capture. Indicates the need for data integration tools offered by the toolkit.
  • Supplier Tender Desertion: Suppliers abandon tenders when price ceilings fall below cost. OBCs could offer more flexible models.
  • Rationale for Estimated Numbers: The estimated R$ 13.2-38.5 billion annual SUS high-cost drug spend is a multi-step estimation based on total market size and assumed proportions for SUS spend and high-cost drugs, due to lack of direct data. The 1-5% penetration of OBCs and 0.05-0.15% value capture are assumptions reflecting the early stage of OBC adoption and a plausible capture rate for an enabling technology based on the value of managed expenditure.

• Calculated Potential Addressable Market:

  • Formula: (Estimated Annual SUS High-Cost Drug Spend) * (Potential % Managed via OBCs) * (Potential % Value Capture by Toolkit)
  • Estimated Annual SUS High-Cost Drug Spend: R$ 13.2 billion - R$ 38.5 billion
  • Potential % Managed via OBCs: 1% - 5%
  • Potential % Value Capture: 0.05% - 0.15%
  • Addressable Market (Range):
    • Lower Bound: R$ 13.2 billion * 1% * 0.05% = R$ 132 million * 0.05% = R$ 0.066 million = R$ 66,000 per year
    • Upper Bound: R$ 38.5 billion * 5% * 0.15% = R$ 1.925 billion * 0.15% = R$ 2.8875 million = R$ 2.9 million per year (rounded)
  • Potential Addressable Market Range (Annual): R$ 0.07 million to R$ 2.9 million

7. Clinically-validated Brazilian phytotherapeutics (Amazon & cerrado actives)

• Key Assumptions and Detailed Rationale:

  • Estimated Annual Market Size of Target Product Categories (Phytotherapeutics, OTC Herbal/Natural) in Brazil: The whitespace focuses on plant-based medicines. The text mentions strong growth in OTC vitamin/herbal sales (+14% YoY), indicating consumer interest in this area. While a precise market size for "phytotherapeutics" or "herbal/natural" products specifically isn't detailed, it's a part of the broader health and wellness market, including OTCs. Estimating the current market size for regulated phytotherapeutics and related herbal/natural products in Brazil to be between R$ 3 billion and R$ 8 billion annually provides a base for the potential market where clinically-validated products would compete or expand.
  • Potential Market Share Achievable by New Clinically-Validated Products: New products backed by rigorous clinical validation can compete more effectively based on efficacy and trust, potentially gaining market share from less-validated products or capturing consumers seeking evidence-based natural options. Achieving a market share of 5% to 15% of the estimated existing market over the 2024-2028 period is a plausible target for a focused initiative bringing validated products to market.

• Researched Numbers with Rationale and Sources:

  • OTC Vitamin/Herbal Sales Growth: +14% YoY. Indicates strong consumer demand for related products.
  • Global Demand for Plant-Based Rx: Mentioned as a trend. Suggests potential for higher-tier products.
  • Trust Gap on Efficacy: Noted in the pain points. Clinical validation directly addresses this pain point.
  • Biodiversity Law (ABS): Provides a framework for benefit sharing. Regulatory support for utilizing Brazilian actives.
  • SUS Fitomedicine List: Exists for procurement. Indicates public health system recognition.
  • Rationale for Estimated Numbers: The R$ 3-8 billion estimated market size for phytotherapeutics/natural health products is a broad estimation based on the noted growth in related categories and the general scale of the OTC/wellness market in Brazil. The 5-15% market share capture is an assumption reflecting the potential impact of clinical validation on consumer and prescriber acceptance within this market.

• Calculated Potential Addressable Market:

  • Formula: (Estimated Annual Market Size of Target Product Categories) * (Potential Market Share Achievable by New Clinically-Validated Products)
  • Lower Bound Calculation: R$ 3 billion * 5% = R$ 0.15 billion = R$ 150 million per year
  • Upper Bound Calculation: R$ 8 billion * 15% = R$ 1.2 billion per year
  • Potential Addressable Market Range (Annual): R$ 150 million to R$ 1.2 billion

8. Net-zero, photovoltaic-powered pharmaceutical plant with Scope 1-3 reporting

• Key Assumptions and Detailed Rationale:

  • Estimated Annual Pharmaceutical Manufacturing Spend Sensitive to Green Premium in Brazil: This whitespace is a B2B offering (green manufacturing services). The market value is tied to the manufacturing spend by pharmaceutical companies who are willing to pay a premium for sustainable production. Companies targeting export markets (facing potential carbon taxes like EU CBAM) or multinational corporations with global ESG commitments are likely candidates. While the total manufacturing spend in Brazil isn't precisely known, estimating the portion of contract manufacturing (CMO) or internal manufacturing by ESG-sensitive companies as being between R$ 2 billion and R$ 5 billion annually provides a base for the potential market where a green premium could be applied.
  • Potential Percentage of This Spend Captured by Net-Zero Plants: A new net-zero facility would need to secure manufacturing contracts within this green-sensitive segment. Capturing 5% to 15% of this estimated addressable manufacturing spend over the 2024-2028 period represents a plausible market penetration rate for securing production volume in an emerging niche.
  • Average Green Premium Percentage: The value captured by the plant from its green attributes is the premium charged on its manufacturing services. While difficult to pinpoint, a modest premium of 2% to 5% on the manufacturing service fee or cost is assumed, reflecting the value of meeting ESG requirements, potential cost savings passed on (e.g., energy), or brand positioning benefits for the client.

• Researched Numbers with Rationale and Sources:

  • ESG Importance: Multinationals add ESG clauses to CMO RFPs; EU CBAM may tax carbon-intense imports; Consumers cite sustainability. Indicates growing demand for green manufacturing.
  • Cheaper Solar in Northeast: Noted as an opportunity. Supports the feasibility of a PV-powered plant.
  • Rationale for Estimated Numbers: The estimated R$ 2-5 billion annual manufacturing spend sensitive to green premium is an assumption based on the potential size of the CMO market and manufacturing by ESG-focused companies, due to lack of direct data. The 5-15% capture rate is an assumption of securing contracts within this niche. The 2-5% green premium is an assumption based on typical price differences for sustainable goods/services where data is available, applied to a manufacturing context. The addressable market calculation specifically estimates the value of the premium captured.

• Calculated Potential Addressable Market:

  • Formula: (Estimated Annual Pharmaceutical Manufacturing Spend Sensitive to Green Premium in Brazil) * (Potential Percentage of This Spend Captured) * (Average Green Premium Percentage)
  • Estimated Annual Manufacturing Spend Sensitive to Green Premium: R$ 2 billion - R$ 5 billion per year
  • Potential Percentage Captured: 5% - 15%
  • Average Green Premium Percentage: 2% - 5%
  • Addressable Market (Range - for the premium):
    • Lower Bound Calculation: R$ 2 billion * 5% * 2% = R$ 2 million per year
    • Upper Bound Calculation: R$ 5 billion * 15% * 5% = R$ 37.5 million per year
  • Potential Addressable Market Range (Annual): R$ 2 million to R$ 37.5 million

References

1. Abradilan. Setor farmacêutico cresce 12,7 % em 2024, mas reajuste autorizado gera dúvidas. https://abradilan.com.br/setor-farmaceutico-cresce-127-em-2024-mas-reajuste-autorizado-gera-duvidas-e-impacto-no-bolso-do-consumidor/
2. Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/nova-industria-brasil-contribuira-para-fortalecer-producao-de-medicamentos
3. Anvisa. Aprovado novo marco regulatório de BPF. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2023/aprovado-novo-marco-regulatorio-de-bpf
4. CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos. https://www.cnnbrasil.com.br/business/brasil-importa-90-da-materia-prima-para-a-producao-de-medicamentos/
5. Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025). https://drfisiologia.com.br/industria-farmaceutica-brasileira-e-suas-tendencias-2025/
6. Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025. https://febrafar.com.br/noticias/varejo-farmaceutico-2024-2025/
7. Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. https://www.gov.br/pt-br/noticias/industria-e-comercio/2024/01/nova-industria-brasil-contribuira-para-fortalecer-producao-de-medicamentos
8. Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://medicnasa.com.br/tres-grandes-grupos-de-redes-de-farmacias-concentram-40-do-mercado-no-brasil/
9. Ipea. Purchase of medicines by the Brazilian federal government. https://www.ipea.gov.br/portal/index.php?option=com_content&view=article&id=42562:compra-de-medicamentos-pelo-governo-federal-brasileiro&catid=11&lang=en&Itemid=10
10. Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país. https://medicnasa.com.br/noticias/brasileiros-preferem-producao-nacional/
11. Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://revistamedicinasa.com.br/mercado/tres-grandes-grupos-de-redes-de-farmacias-concentram-40-do-mercado
12. VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar. https://veja.abril.com.br/economia/90-dos-brasileiros-dizem-que-producao-nacional-de-remedios-deve-aumentar
13. Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?. https://omnihospitalar.com.br/blog/processo-de-distribuicao-de-medicamentos
14. Omni Hospitalar. Distribuição refrigerada e desafios logísticos. https://omnihospitalar.com.br/blog/distribuicao-refrigerada-medicamentos
15. Natcofarma. Varejo farmacêutico: Confira as principais tendências. https://natcofarma.com.br/blog/tendencias-varejo-farmaceutico
16. Vernalha Pereira. Novas regras da Anvisa e o seu impacto no registro de medicamentos para a indústria farmacêutica. https://vernalhapereira.com.br/artigos/anvisa-impacto-registro

(Note: References from the vertexaisearch.cloud.google.com domain were omitted as per instructions. Only publicly accessible URLs are included.)